Sharon Townson Sells 3,000 Shares of Monte Rosa Therapeutics (NASDAQ:GLUE) Stock

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) insider Sharon Townson sold 3,000 shares of the firm’s stock in a transaction on Tuesday, June 23rd. The shares were sold at an average price of $20.00, for a total value of $60,000.00. Following the transaction, the insider owned 67,845 shares in the company, valued at approximately $1,356,900. This trade represents a 4.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Sharon Townson also recently made the following trade(s):

• On Wednesday, June 17th, Sharon Townson sold 3,000 shares of Monte Rosa Therapeutics stock. The stock was sold at an average price of $19.00, for a total transaction of $57,000.00.

Monte Rosa Therapeutics Price Performance

NASDAQ GLUE opened at $22.28 on Friday. Monte Rosa Therapeutics, Inc. has a 1 year low of $4.12 and a 1 year high of $25.77. The firm has a market cap of $1.88 billion, a price-to-earnings ratio of -15.05 and a beta of 1.60. The company has a fifty day moving average price of $18.96 and a 200-day moving average price of $18.63.

Monte Rosa Therapeutics (NASDAQ:GLUE) last announced its earnings results on Thursday, May 7th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.06). Monte Rosa Therapeutics had a negative net margin of 302.69% and a negative return on equity of 40.99%. The firm had revenue of $4.21 million during the quarter, compared to analysts’ expectations of $10.95 million. On average, research analysts anticipate that Monte Rosa Therapeutics, Inc. will post -1.23 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have commented on GLUE. Weiss Ratings raised shares of Monte Rosa Therapeutics from a “sell (d-)” rating to a “sell (d)” rating in a research report on Monday, May 11th. JPMorgan Chase & Co. upped their target price on Monte Rosa Therapeutics from $30.00 to $31.00 and gave the company an “overweight” rating in a report on Monday, May 11th. Guggenheim decreased their price target on Monte Rosa Therapeutics from $34.00 to $30.00 and set a “buy” rating for the company in a research report on Wednesday, March 18th. Wall Street Zen lowered Monte Rosa Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. Finally, Wells Fargo & Company cut their price objective on Monte Rosa Therapeutics from $30.00 to $29.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 18th. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Monte Rosa Therapeutics has an average rating of “Moderate Buy” and an average target price of $32.50.

Institutional Trading of Monte Rosa Therapeutics

Several hedge funds have recently made changes to their positions in GLUE. Seven Fleet Capital Management LP grew its stake in shares of Monte Rosa Therapeutics by 463.3% during the 1st quarter. Seven Fleet Capital Management LP now owns 22,530 shares of the company’s stock worth $371,000 after acquiring an additional 18,530 shares during the period. Bank of America Corp DE increased its holdings in Monte Rosa Therapeutics by 73.3% in the 1st quarter. Bank of America Corp DE now owns 387,542 shares of the company’s stock worth $6,375,000 after acquiring an additional 163,971 shares during the last quarter. Janus Henderson Group PLC bought a new stake in Monte Rosa Therapeutics in the 1st quarter valued at about $11,294,000. Empowered Funds LLC raised its stake in Monte Rosa Therapeutics by 9.8% in the 1st quarter. Empowered Funds LLC now owns 305,398 shares of the company’s stock valued at $5,024,000 after acquiring an additional 27,321 shares during the period. Finally, Exome Asset Management LLC purchased a new stake in Monte Rosa Therapeutics during the first quarter valued at about $2,953,000. 79.96% of the stock is currently owned by institutional investors.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.